Teva to Present at Barclays Global Healthcare Conference and Leerink Partners Global Healthcare Conferences in March
2025 Community Routes: Access to Mental Health Care Grants Awarded to Clinics in Alabama, Mississippi, and Texas, Funded by Teva Pharmaceuticals
Teva and Medincell Announce FDA Acceptance of Supplemental New Drug Application for UZEDY(R) (risperidone) Extended-Release Injectable Suspension as a Treatment for Patients with Bipolar I Disorder
Teva and Sanofi Present New Positive Phase 2b Study Results at ECCO 2025 Reinforcing Best-in-Class Potential of Duvakitug (Anti-TL1A) in Ulcerative Colitis and Crohn’s Disease
Teva and Alvotech Announce SELARSDI™ (ustekinumab-aekn) Injection Now Available in the U.S.
Teva to Host Conference Call on February 24, 2025 to Discuss New Data Presented for Duvakitug (anti-TL1A) Positive Phase 2b results at the 20th Annual Congress of the European Crohn's and Colitis Organisation (ECCO)
Alvotech and Teva Announce Filing Acceptance of U.S. Biologics License Application for AVT06, a Proposed Biosimilar to Eylea® (aflibercept)
Teva Delivers Second Consecutive Year of Growth; Announces Strong Financial Results in Fourth Quarter and Full Year 2024, Led by Generics Performance and Innovative Portfolio Growth
Alvotech and Teva Announce Filing Acceptance of U.S. Biologics License Applications for AVT05, a Proposed Biosimilar to Simponi® and Simponi Aria® (golimumab)
Teva Announces Collaboration to Commercialize Formycon’s Biosimilar Candidate to Eylea® (aflibercept) in major parts of Europe and in Israel
Teva and Samsung Bioepis Enter into a Strategic Partnership for Commercialization of EPYSQLI® (eculizumab-aagh) in the United States
Teva to Present at the 43rd Annual J.P. Morgan Healthcare Conference
Teva to Host Conference Call to Discuss Fourth Quarter and Full Year 2024 Financial Results and 2025 Financial Guidance at 8 a.m. ET on January 29, 2025
Teva and Sanofi Announce Duvakitug (Anti-TL1A) Positive Phase 2b Results Demonstrating Best-in-Class Potential in Ulcerative Colitis and Crohn’s Disease
Teva Announces New Patient Access Program with Direct Relief
Teva Announces Agreement to Divest Teva-Takeda, its Business Venture in Japan
Teva Presents Positive Efficacy and Safety Data of AJOVY® (fremanezumab) for the Prevention of Episodic Migraine in Children and Adolescents from Phase 3 SPACE Trial
Teva to Present at the 7th Annual Evercore ISI HealthCONx Conference
Teva to Present at the Jefferies London Healthcare Conference
Teva Announces Strong Financial Results for the Third Quarter of 2024, led by Generics Performanc...
Teva Presents New Tardive Dyskinesia Data at Psych Congress 2024 from the IMPACT-TD Registry, Rev...
Teva Presents Latest Schizophrenia Treatment Research, Including Phase 3 SOLARIS Trial Results De...
Teva Statement on European Commission Decision; Company to Appeal
Alvotech and Teva Announce U.S. FDA Approval of Additional Presentation of SELARSDI™ (ustekinumab...
Teva Prolia® (Denosumab) Biosimilar Candidate is Accepted for Review by U.S. FDA and EU EMA
Teva and mAbxience Expand Strategic Partnership to include an additional Oncology Biosimilar Cand...
Teva Announces Launch of the First and Only Generic Version of Sandostatin® LAR Depot (octreotide...
Teva to Host Conference Call to Discuss Third Quarter 2024 Financial Results at 8 a.m. ET on Nove...
Teva Announces Long Term Efficacy and Safety of Deutetrabenazine in European Patients with Debili...
Teva Presents New Phase 3 Efficacy, Safety and Tolerability Data from SOLARIS Trial Evaluating TE...
New Data Provide Treatment Insights into Options for Switching Adult Patients Diagnosed with Schi...
Teva to Present at the Bank of America 2024 Global Healthcare Conference
Teva to Present at the Morgan Stanley 22nd Annual Global Healthcare Conference
Teva Announces Strong Growth in Second Quarter Revenues mainly driven by Generics Products in All...
Teva and Sanofi Announce Accelerated Timeline for Anti-TL1A Phase 2b Program in Patients with Inf...
Teva Announces First Phase 3 Evidence of Efficacy and Safety of an Anti-CGRP Monoclonal Antibody ...
Teva to Host Conference Call to Discuss Second Quarter 2024 Financial Results at 8 a.m. ET on Jul...
New AJOVY® (fremanezumab) Migraine Prevention Data Challenges Treatment Pauses
Teva Reaches Agreement With the Israel Tax Authority to Resolve All Pending Litigation for the Co...
Teva Announces Launch of Authorized Generic of Victoza® (liraglutide injection 1.8mg), in the Uni...
Teva to Present at the Goldman Sachs 45th Annual Global Healthcare Conference
New Data Provide Schizophrenia Treatment Insights into Switching to UZEDY® (risperidone) Extended...
Teva Presents First Real-World Data from the IMPACT-TD Registry Study at Psych Congress Elevate 2024
Teva Announces AUSTEDO® XR (deutetrabenazine) Extended-Release Tablets Now U.S. FDA Approved as a...
Teva and Alvotech Announce SIMLANDI® (adalimumab-ryvk) Injection Now Available in the U.S.
Teva Announces Appointment of Matthew Shields to Executive Vice President, Teva Global Operations
Teva Reports First Quarter 2024 Financial Results and Reaffirms 2024 Financial Outlook
Teva and Medincell Announce Positive Phase 3 Efficacy Results from SOLARIS Trial Evaluating TEV-‘...
Teva to Present at the 2024 Bank of America Healthcare Conference
U.S. Commercialization Agreement with Quallent to Drive Patient Savings with First High-Concentra...
You are about to leave the Teva Pharmaceuticals global website
The website you are about to access may be governed by different regional policies, regulations or advertising codes. Please be sure to read the privacy policy and terms of use of the websites that you visit.
Teva Pharmaceuticals is not responsible for the accuracy or compliance with laws of information on any third party websites.
